| Clinical data | |
|---|---|
| Trade names | Dorner |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | 50–70% |
| Metabolism | Unknown |
| Eliminationhalf-life | 35–40 minutes |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C24H30O5 |
| Molar mass | 398.499 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Beraprost is a pharmaceutical drug used in several Asian countries, including Japan and South Korea, as avasodilator and antiplatelet agent.[1] It is classified as aprostacyclin analog.[1][2]
It has been studied for the treatment ofpulmonary hypertension and for use in avoidingreperfusion injury.
As an analog of prostacyclin PGI2, beraprost affectsvasodilation, which in turn lowersblood pressure. Beraprost also inhibitsplatelet aggregation, though the role this phenomenon may play in relation to pulmonary hypertension has yet to be determined.
Beraprost is administered orally as a pill available in strength of 20 mcg. Dose ranges from 60 to 180 mcg in divided doses after meals.